Figure 2
Intratumor injection with Ad5IL-12 or 1 week treatment with RU486 attenuates the growth of human LNCaP tumors. Xenograft tumors established in NOD.scid mice were treated at week 3 by IT injection with 50 μl of PBS containing 5 × 108 pfu of Ad5IL-12 (filled squares) or the control DL70-3 vector (empty squares) or PBS alone (empty circles). In addition, another set of mice were treated with Ad5IL-12 IT and given daily IP injections of RU486 for 7 days (black triangles). Data points are expressed as the mean ± SE. n = 8 for each data point. * indicates statistical significance of P < 0.05 for Ad5IL-12 + RU486 treatments alone compared to controls. Tumor volumes measured at 8 weeks were 3353 ± 532 mm3 for PBS, 3197 ± 600 mm3 for DL70-3, 1284 ± 350 for RU486, 1073 ± 226 mm3 for Ad5IL-12 and 1015 ± 321 mm3 for Ad5IL-12 + RU486 treatment groups.